238 related articles for article (PubMed ID: 35019133)
1. NEOADJUVANT CHEMORADIOTHERAPY FOLLOWED BY TRANSHITAL ESOPHAGECTOMY IN LOCALLY ADVANCED ESOPHAGEAL SQUAMOUS CELL CARCINOMA: IMPACT OF PATHOLOGICAL COMPLETE RESPONSE.
Alves IPF; Tercioti Junior V; Coelho Neto JS; Ferrer JAP; Carvalheira JBC; Pereira EB; Lopes LR; Andreollo NA
Arq Bras Cir Dig; 2022; 34(3):e1621. PubMed ID: 35019133
[TBL] [Abstract][Full Text] [Related]
2. Neoadjuvant chemoradiotherapy with concurrent cisplatin/5-fluorouracil is associated with increased pathologic complete response and improved survival compared to carboplatin/paclitaxel in patients with locally advanced esophageal cancer.
Haisley KR; Hart KD; Nabavizadeh N; Bensch KG; Vaccaro GM; Thomas CR; Schipper PH; Hunter JG; Dolan JP
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475724
[TBL] [Abstract][Full Text] [Related]
3. Neoadjuvant chemotherapy versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a single-Centre, open-label, randomized, controlled, clinical trial (HCHTOG1903).
Sun HB; Xing WQ; Liu XB; Zheng Y; Yang SJ; Wang ZF; Liu SL; Ba YF; Zhang RX; Liu BX; Fan CC; Chen PN; Liang GH; Yu YK; Liu Q; Wang HR; Li HM; Li ZX;
BMC Cancer; 2020 Apr; 20(1):303. PubMed ID: 32293362
[TBL] [Abstract][Full Text] [Related]
4. Neoadjuvant chemoradiotherapy with docetaxel, cisplatin, and 5-fluorouracil (DCF-RT) for locally advanced esophageal squamous cell carcinoma.
Sasaki K; Uchikado Y; Omoto I; Arigami T; Osako Y; Noda M; Okumura H; Maemura K; Higashi R; Yoshiura T; Natsugoe S
Cancer Chemother Pharmacol; 2019 Mar; 83(3):581-587. PubMed ID: 30623230
[TBL] [Abstract][Full Text] [Related]
5. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
[TBL] [Abstract][Full Text] [Related]
6. PATHOLOGIC COMPLETE RESPONSE (YPT0 YPN0) AFTER CHEMOTHERAPY AND RADIOTHERAPY NEOADJUVANT FOLLOWED BY ESOPHAGECTOMY IN THE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS.
Andreollo NA; Beraldo GC; Alves IPF; Tercioti-Junior V; Ferrer JAP; Coelho-Neto JS; Lopes LR
Arq Bras Cir Dig; 2018 Dec; 31(4):e1405. PubMed ID: 30539980
[TBL] [Abstract][Full Text] [Related]
7. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
Gong L; Mao W; Chen Q; Jiang Y; Fan Y
Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of paclitaxel plus carboplatin versus paclitaxel plus cisplatin in neoadjuvant chemoradiotherapy for patients with locally advanced esophageal carcinoma: a retrospective study.
Jiang L; Zhu J; Chen X; Wang Y; Wu L; Wan G; Han Y; Leng X; Peng L; Wang Q
Radiat Oncol; 2022 Dec; 17(1):218. PubMed ID: 36585731
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two neoadjuvant chemoradiotherapy regimens in patients with potentially curable esophageal carcinoma.
Blom RL; Sosef MN; Nap M; Lammering G; van den Berkmortel F; Hulshof MC; Meijer SL; Wilmink HW; van Berge Henegouwen MI
Dis Esophagus; 2014; 27(4):380-7. PubMed ID: 24006852
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemoradiotherapy versus neoadjuvant chemotherapy followed by minimally invasive esophagectomy for locally advanced esophageal squamous cell carcinoma: a prospective multicenter randomized clinical trial.
Tang H; Wang H; Fang Y; Zhu JY; Yin J; Shen YX; Zeng ZC; Jiang DX; Hou YY; Du M; Lian CH; Zhao Q; Jiang HJ; Gong L; Li ZG; Liu J; Xie DY; Li WF; Chen C; Zheng B; Chen KN; Dai L; Liao YD; Li K; Li HC; Zhao NQ; Tan LJ
Ann Oncol; 2023 Feb; 34(2):163-172. PubMed ID: 36400384
[TBL] [Abstract][Full Text] [Related]
11. Concurrent radiotherapy cannot provide superiority of surgical oncological outcome and long-term survival rate in locally advanced esophageal squamous cell carcinoma patients receiving neoadjuvant chemotherapy followed by minimally invasive esophagectomy.
Wang YJ; Bao T; Li KK; Xie XF; He XD; Zhao XL; Guo W
Surg Endosc; 2023 Sep; 37(9):7073-7082. PubMed ID: 37380741
[TBL] [Abstract][Full Text] [Related]
12. CMISG1701: a multicenter prospective randomized phase III clinical trial comparing neoadjuvant chemoradiotherapy to neoadjuvant chemotherapy followed by minimally invasive esophagectomy in patients with locally advanced resectable esophageal squamous cell carcinoma (cT
Tang H; Tan L; Shen Y; Wang H; Lin M; Feng M; Xu S; Guo W; Qian C; Liu T; Zeng Z; Hou Y; Yu Z; Jiang H; Li Z; Chen C; Lian C; Du M; Li H; Xie D; Yin J; Zhao N; Wang Q
BMC Cancer; 2017 Jun; 17(1):450. PubMed ID: 28659128
[TBL] [Abstract][Full Text] [Related]
13. Clinical tools do not predict pathological complete response in patients with esophageal squamous cell cancer treated with definitive chemoradiotherapy.
Molena D; Sun HH; Badr AS; Mungo B; Sarkaria IS; Adusumilli PS; Bains MS; Rusch VW; Ilson DH; Rizk NP
Dis Esophagus; 2014; 27(4):355-9. PubMed ID: 24033404
[TBL] [Abstract][Full Text] [Related]
14. Phase II study of metabolic response to one-cycle chemotherapy in patients with locally advanced esophageal squamous cell carcinoma.
Huang TC; Lin CC; Wu YC; Chia-Hsien Cheng J; Lee JM; Wang HP; Huang PM; Hsu FM; Yeh KH; Cheng AL; Tzen KY; Hsu CH
J Formos Med Assoc; 2019 Jun; 118(6):1024-1030. PubMed ID: 30502100
[TBL] [Abstract][Full Text] [Related]
15. Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
Chiu CH; Chen WH; Wen YW; Yeh CJ; Chao YK; Chang HK; Tseng CK; Liu YH
Dis Esophagus; 2016 Aug; 29(6):634-41. PubMed ID: 26175202
[TBL] [Abstract][Full Text] [Related]
16. A phase-II/III randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-IIB/III esophageal squamous cell carcinoma.
Ni W; Yu S; Zhang W; Xiao Z; Zhou Z; Chen D; Feng Q; Liang J; Lv J; Gao S; Mao Y; Xue Q; Sun K; Liu X; Fang D; Li J; Wang D
BMC Cancer; 2020 Feb; 20(1):130. PubMed ID: 32070309
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant Chemoradiotherapy Using Cisplatin and 5-Fluorouracil (PF) Versus Carboplatin and Paclitaxel (CROSS Regimen) for Esophageal Squamous Cell Carcinoma (ESCC): A Propensity Score-matched Study.
Wong IYH; Lam KO; Zhang RQ; Chan WWL; Wong CLY; Chan FSY; Kwong DLW; Law SYK
Ann Surg; 2020 Nov; 272(5):779-785. PubMed ID: 32833766
[TBL] [Abstract][Full Text] [Related]
18. Prospective, open, multicentre Phase I/II trial to assess safety and efficacy of neoadjuvant radiochemotherapy with docetaxel and cisplatin for esophageal carcinoma.
Ma HB; Di ZL; Wen J; Ke Y; Sun X; Ren J
Jpn J Clin Oncol; 2015 Feb; 45(2):169-75. PubMed ID: 25416813
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of neoadjuvant chemoradiotherapy using cisplatin and 5-fluorouracil followed by esophagectomy for resectable, locally advanced esophageal squamous cell carcinoma.
Murakami Y; Hamai Y; Emi M; Hihara J; Imano N; Takeuchi Y; Takahashi I; Nishibuchi I; Kimura T; Okada M; Nagata Y
J Radiat Res; 2018 Sep; 59(5):616-624. PubMed ID: 29939306
[TBL] [Abstract][Full Text] [Related]
20. Validation of the post-neoadjuvant staging system of the American joint committee on cancer, 8th edition, in patients treated with neoadjuvant chemoradiotherapy followed by curative esophagectomy for localized esophageal squamous cell carcinoma.
Kang J; Lee HP; Kim HR; Kim JH; Jung HY; Lee GH; Song HJ; Kim DH; Choi KD; Ahn JY; Ryu JS; Cho KJ; Lee MY; Kim SB; Kim YH; Park SR
Surg Oncol; 2020 Dec; 35():491-497. PubMed ID: 33130441
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
